المؤلفون: Charite University, Berlin, Germany, Ruhr University of Bochum, Technische Universität Dresden, University Hospital, Lille, Casa di Cura IGEA, General University Hospital, Prague, Hoffmann-La Roche, Bristol-Myers Squibb, Imcyse SA, AB Science, Nocturne UG, Aalto University

المصدر: Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study

المؤلفون: Saidia, Anissa, Rym, François, Florence, Casas, François, Mechaly, Ilana, Venteo, Stéphanie, Veechi, Joseph, T, Ruel, Jérôme, Puel, Jean-Luc, Wang, Jing

المساهمون: Institut des Neurosciences de Montpellier (INM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Dynamique du Muscle et Métabolisme (DMEM), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université de Montpellier (UM), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), This work was supported by the Fondation Gueules Cassées (65-2022). A.R.S. was financedby a PhD fellowship from the Fondation Gueules Cassées (66-2022) and another fellowship (UMn◦ 200760) from The AB science company. J.T.V. was supported by the Chateaubriand Fellowshipof the Office for Science & Technology of the Embassy of France in the United States, NIH NIGMST32-GM007337 and NIH NIDCD F31-DC020371.

المصدر: ISSN: 2076-3921.

مصطلحات موضوعية: synaptopathy, glutamate excitotoxicity, kainic acid, AMPA receptors, oxidative stress, antioxidants, neurotrophic factor, [SDV]Life Sciences [q-bio]

Relation: WOS: 001168243700001

الاتاحة: https://hal.inrae.fr/hal-04496075
https://hal.inrae.fr/hal-04496075v1/document
https://hal.inrae.fr/hal-04496075v1/file/antioxidants-13-00149.pdf
https://doi.org/10.3390/antiox13020149

المؤلفون: Lortholary, Olivier, Chandesris, Marie, Olivia, Livideanu, Cristina, Bulai, Paul, Carle F, Guillet, Gérard, Jassem, Ewa, Niedoszytko, Marek, Barete, Stéphane, Verstovsek, Srdan, Grattan, Clive, Damaj, Gandhi, Canioni, Danielle, Fraitag, Sylvie, Lhermitte, Ludovic, Lavialle, Sophie, Georgin, Frenzel, Laurent, Afrin, Lawrence, B, Hanssens, Katia, Agopian, Julie, Gaillard, Raphaël, Kinet, Jean-Pierre, Auclair, Christian, Mansfield, Colin, Moussy, Alain, Dubreuil, Patrice, Hermine, Olivier

المساهمون: Centre d'infectiologie Necker-Pasteur CHU Necker, Institut Pasteur Paris (IP)-Hôpital Necker - Enfants Malades AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de référence des mastocytoses (CEREMAST), Hôpital Necker - Enfants Malades AP-HP, Université Paris Descartes - Paris 5 (UPD5), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie ), University of Gdańsk (UG), Université Pierre et Marie Curie - Paris 6 (UPMC), MD Anderson Cancer Center Houston, The University of Texas Health Science Center at Houston (UTHealth), Norfolk & Norwich University Hospital, Norfolk & Norwich University Hospital, Colney Lane, Institut d'Hématologie de Basse-Normandie (IHBN), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse Caen (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER, Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Tenon AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Minnesota Twin Cities (UMN), University of Minnesota System (UMN), Histopathologie humaine et Modèles animaux, Institut Pasteur Paris (IP), Harvard Medical School Boston (HMS), Laboratoire de Biologie et de Pharmacologie Appliquée (LBPA), École normale supérieure - Cachan (ENS Cachan)-Centre National de la Recherche Scientifique (CNRS), AB Science, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes (IPC), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), AB Science (Paris, France).

المصدر: ISSN: 0140-6736.

مصطلحات موضوعية: MESH: Adult, MESH: Aged, 80 and over, MESH: Asthenia, MESH: Diarrhea, MESH: Double-Blind Method, MESH: Exanthema, MESH: Female, MESH: Humans, MESH: Male, MESH: Mastocytosis, Systemic, MESH: Middle Aged, MESH: Protein Kinase Inhibitors, MESH: Severity of Illness Index, MESH: Thiazoles, MESH: Treatment Outcome, MESH: Urticaria, MESH: Young Adult, [SDV]Life Sciences [q-bio], [SDV.CAN]Life Sciences [q-bio]/Cancer

Relation: info:eu-repo/semantics/altIdentifier/pmid/28069279; hal-01787376; https://hal.science/hal-01787376; https://hal.science/hal-01787376/document; https://hal.science/hal-01787376/file/Masitinib%20for%20treatment%20of%20severely%20symptomatic%20indolent%20systemic%20mastocytosis%20a%20randomised,%20placebo%20controlled%20phase%203%20study.pdf; PUBMED: 28069279

الاتاحة: https://hal.science/hal-01787376
https://hal.science/hal-01787376/document
https://hal.science/hal-01787376/file/Masitinib%20for%20treatment%20of%20severely%20symptomatic%20indolent%20systemic%20mastocytosis%20a%20randomised,%20placebo%20controlled%20phase%203%20study.pdf
https://doi.org/10.1016/S0140-6736(16)31403-9

المؤلفون: Hammam, Kahina, Saez-Ayala, Magali, Rebuffet, Etienne, Gros, Laurent, Lopez, Sophie, Hajem, Bérengère, Humbert, Martine, Baudelet, Emilie, Audebert, Stéphane, Betzi, Stéphane, Lugari, Adrien, Combes, Sébastien, Letard, Sébastien, Castéran, Nathalie, Mansfield, Colin, D., Moussy, Alain, de Sepulveda, Paulo, Morelli, Xavier, Dubreuil, Patrice

المساهمون: Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes (IPC), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), AB Science SA, AB Science, ARC Grant n° SL220130606659

المصدر: ISSN: 2041-1723.

مصطلحات موضوعية: [CHIM.CHEM]Chemical Sciences/Cheminformatics, [CHIM.CRIS]Chemical Sciences/Cristallography, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [CHIM.ORGA]Chemical Sciences/Organic chemistry, [CHIM.THER]Chemical Sciences/Medicinal Chemistry, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], [SDV.BBM.BP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biophysics, [SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Structural Biology [q-bio.BM], [SDV.BBM.MN]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular Networks [q-bio.MN]

Relation: hal-01643359; https://hal.science/hal-01643359; https://hal.science/hal-01643359/document; https://hal.science/hal-01643359/file/article55.pdf

الاتاحة: https://hal.science/hal-01643359
https://hal.science/hal-01643359/document
https://hal.science/hal-01643359/file/article55.pdf
https://doi.org/10.1038/s41467-017-01582-5

المؤلفون: Dubois, Bruno, López-Arrieta, Jesús, Lipschitz, Stanley, Triantafyllos, Doskas, Spiru, Luiza, Moroz, Svitlana, Venger, Olena, Vermersch, Patrick, Moussy, Alain, Mansfield, Colin, D, Hermine, Olivier, Tsolaki, Magda, Doskas, Triantafyllos

المساهمون: CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre des Maladies Cognitives et Comportementales Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), University of Medicine and Pharmacy “Carol Davila” (UMPCD), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), AB Science, Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Aristotle University of Thessaloniki

المصدر: ISSN: 1758-9193 ; Alzheimer's Research and Therapy ; https://u-paris.hal.science/hal-04087090 ; Alzheimer's Research and Therapy, 2023, 15 (1), pp.39. ⟨10.1186/s13195-023-01169-x⟩.

مصطلحات موضوعية: Alzheimer's disease Mast cells Microglia Tyrosine kinase inhibitor, Alzheimer's disease, Mast cells, Microglia, Tyrosine kinase inhibitor, Alzheimer’s disease, MESH: Humans, MESH: Alzheimer Disease, MESH: Activities of Daily Living, MESH: Memantine, MESH: Thiazoles, [SDV]Life Sciences [q-bio]

Relation: info:eu-repo/semantics/altIdentifier/pmid/36849969; PUBMED: 36849969; PUBMEDCENTRAL: PMC9972756

الاتاحة: https://u-paris.hal.science/hal-04087090
https://u-paris.hal.science/hal-04087090v1/document
https://u-paris.hal.science/hal-04087090v1/file/s13195-023-01169-x.pdf
https://doi.org/10.1186/s13195-023-01169-x

المؤلفون: Corren, Jonathan, Menzies-Gow, Andrew, Bimmel, Johan, McGuinness, Anthony, Almqvist, Gun, Bowen, Karin, Griffiths, Janet M, Ponnarambil, Sandhia, Bourdin, Arnaud, Israel, Elliot, Colice, Gene, Brightling, Christopher E, Wechsler, Michael E

المساهمون: AstraZeneca, Genentech, Vectura, Optinose, Sanofi, Teva Pharmaceuticals, Novartis, Boehringer Ingelheim, Cephalon Pharmaceuticals, GlaxoSmithKline, Sanofi-Regeneron Pharmaceuticals, Actelion, Chiesi, Galapagos, Merck, Roche, Vertex, 4D Pharma, AB Science, Amgen, Avillion, Biometry, Cowen, Equillium, Pneuma Respiratory, PPS Health, Regeneron Pharmaceuticals, Sienna Biopharmaceuticals, Gossamer Bio, Mologic, resTORbio

المصدر: Immunotherapy ; volume 15, issue 16, page 1327-1340 ; ISSN 1750-743X 1750-7448

الاتاحة: http://dx.doi.org/10.2217/imt-2023-0109
https://www.tandfonline.com/doi/pdf/10.2217/imt-2023-0109

المؤلفون: Vermersch, Patrick, Benrabah, Rabah, Schmidt, Nicolas, Zéphir, Hélène, Clavelou, Pierre, Vongsouthi, Cyrille, Dubreuil, Patrice, Moussy, Alain, Hermine, Olivier

المساهمون: Laboratoire d'Immunologie, Faculté de Médecine-Institut de Médecine Prédictive et de Recherche Thérapeutique (IMPRT) : IFR14-EA 2686-Université de Lille, Droit et Santé, Private Practice, Private practice, Service Neurologie CHU Clermont-Ferrand, CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand-CHU Clermont-Ferrand-Pôle Médecine interne, Neurologie, Neurochirurgie, Ophtalmologie CHU Clermont-Ferrand (MNDO), CHU Clermont-Ferrand-CHU Clermont-Ferrand, AB Science, AB Science Headquarter, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes (IPC), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Cytokines, hématopoïèse et réponse immune (CHRI), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), This work was partially financed by INSERM (Institut National de la Santé et de la Recherche Médicale), la Ligue Nationale Contre le Cancer (équipe labellisée PD) and ANR-MRAR (Agence Nationale pour la Recherche, grant Maladies Rares - PD and OH) and INCA (Institut National du Cancer, grant Translationnel - PD and OH).

المصدر: ISSN: 1471-2377 ; BMC Neurology ; https://inserm.hal.science/inserm-00740070 ; BMC Neurology, 2012, 12 (1), pp.36. ⟨10.1186/1471-2377-12-36⟩.

مصطلحات موضوعية: Multiple sclerosis, Primary progressive multiple sclerosis, Secondary progressive multiple sclerosis, Tyrosine kinase inhibitor, Masitinib, Mast cells, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]

Relation: info:eu-repo/semantics/altIdentifier/pmid/22691628; PUBMED: 22691628

الاتاحة: https://inserm.hal.science/inserm-00740070
https://inserm.hal.science/inserm-00740070v1/document
https://inserm.hal.science/inserm-00740070v1/file/1471-2377-12-36.pdf
https://doi.org/10.1186/1471-2377-12-36

المؤلفون: Tilch, Marie Kristin, Visco, Carlo, Kinda, Sandra Bašić, Hermine, Olivier, Kohn, Milena, Besson, Caroline M., Lamure, Sylvain, Duléry, Rémy, Ragaini, Simone, Eyre, Toby Andrew, van Meerten, Tom, Ohler, Anke, Eckerle, Steffen, Dreyling, Martin H., Hess, Geoŗge R., Giné, Eva, da Silva, Maria Gomes

المساهمون: University Medical Center of the Johannes Gutenberg-University Mainz, Università degli studi di Verona = University of Verona (UNIVR), University Hospital Centre Zagreb, Partenaires INRAE, Hôpital Necker - Enfants Malades AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier de Versailles André Mignot (CHV), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Università degli studi di Torino = University of Turin (UNITO), Churchill Hospital Breast Care Unit, Churchill Hospital Oxford Centre for Haematology, University of Groningen Groningen, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Novartis, Roche, Sanofi, Gilead Sciences, Alexion Pharmaceuticals, Celgene, AbbVie, Janssen Pharmaceuticals, M-KT received speakers’ honoraria from Astra Zeneca, Shire Takeda, Hexal. CV served as a advisory board or scientific advisor for Roche, Gilead, Incyte, Beigene, AbbVie, Janssen, Takeda, Novartis, and received research funding from Jannsen, Gentili. SK received honoraria and advisory board for Roche, Sandoz, and Octapharm/Celtrion. OH received grants from Celgene, Alexion, AB Science, and Inatherys. SL received miscellaneous support from Janssen, Gilead, Roche, Abbvie, Sanofi, Novartis, Actelion, Pfizer, honorarium from Gilead, and a research grant from Janssen. RD received personal fees from Takeda, Novartis, and Biotest, nonfinancial support from Gilead. MGdS received research support, travel to scientific conferences, advisory boards from Gilead, research support from Astrazeneca, travel to scientific conferences, advisory boards from Abbvie, advisory boards from JC, travel to scientific conferences, advisory boards, trial steering committee from Roche, advisory boards from Takeda, advisory boards from Bristol Myers Squibb, advisory boards from ADC Therapeutics, and advisory board from Celgene. EG received honoraria from Gilead/Kite, Janssen, Genmab, served as consulting or advisory role in Gilead/Kite, and research Funding from Janssen. TE received honorarium, advisory board honorarium from Roche, received honorarium, research support, and travel to scientific conferences from Gilead, advisory board honorarium from KITE, honorarium from Janssen, honorarium and Travel to scientific conferences from Abbvie, AstraZeneca: Honorarium, Research funding, Loxo Oncology: Advisory Board Honorarium, Trial steering committee, Beigene: Advisory Board Honorarium, Research funding, Incyte: Advisory Board Honorarium, Secura Bio: Advisory Board Honorarium. MD is a HemaSphere editor, receives funding by Abbvie, Bayer, Celgene, Gilead/Kite, Janssen, speaker’s honoraria from Amgen, Astra Zeneca, Bayer, Celgene, Gilead/Kite, Incyte, Janssen, Novartis, Roche, advisory honoraria from Astra Zeneca, Bayer, Beigene, Celgene, Genmab, Gilead/Kite, Incyte, Janssen, Lilly/Loxo, Morphosys, Novartis, Roche. GH receives funding by Roche, Janssen Pharmaceuticals, Celgene and Gilead and speaker’s or advisory honoraria from Janssen, Roche, Celgene, Gilead, Novartis, Incyte, Genmab, Morphosys, Abbvie, and Astra. All the other authors have no conflicts of interest to disclose.

المصدر: ISSN: 2572-9241 ; HemaSphere ; https://hal.science/hal-03673380 ; HemaSphere, 2022, 6 (5), pp.e0711. ⟨10.1097/HS9.0000000000000711⟩.

مصطلحات موضوعية: [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology

Relation: PUBMEDCENTRAL: PMC9000040

الاتاحة: https://hal.science/hal-03673380
https://hal.science/hal-03673380v1/document
https://hal.science/hal-03673380v1/file/hs9-6-e0711.pdf
https://doi.org/10.1097/HS9.0000000000000711

المؤلفون: Davidescu, Lavinia, Ursol, Grygoriy, Korzh, Oleksii, Deshmukh, Vikrant, Kuryk, Lesia, Nortje, Monja-Marie, Godlevska, Olga, Devouassoux, Gilles, Khodosh, Eduard, Israel, Elliot, Moussy, Alain, Mansfield, Colin, Hermine, Olivier, Chanez, Pascal

المساهمون: University of Oradea, Kharkiv Medical Academy of Postgraduate Education, National Academy of Medical Sciences of Ukraine, Hôpital de la Croix-Rousse CHU - HCL, Hospices Civils de Lyon (HCL), Brigham & Women’s Hospital Boston (BWH), Harvard Medical School Boston (HMS), AB Science Paris, France, Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Necker - Enfants Malades AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Clinique des bronches, allergie et sommeil, Centre Hospitalier Universitaire de Saint-Etienne CHU Saint-Etienne (CHU ST-E)

المصدر: ISSN: 1178-6965 ; Journal of Asthma and Allergy ; https://hal.inrae.fr/hal-03782725 ; Journal of Asthma and Allergy, 2022, Volume 15, pp.737-747. ⟨10.2147/JAA.S337284⟩.

مصطلحات موضوعية: asthma clinical trials, asthma medication, mast cells, tyrosine kinases, severe asthma, [SDV.IMM]Life Sciences [q-bio]/Immunology

Relation: info:eu-repo/semantics/altIdentifier/pmid/35698580; hal-03782725; https://hal.inrae.fr/hal-03782725; https://hal.inrae.fr/hal-03782725/document; https://hal.inrae.fr/hal-03782725/file/DavidescuJAA-2022.pdf; PUBMED: 35698580; PUBMEDCENTRAL: PMC9188333; WOS: 000811511200001

الاتاحة: https://hal.inrae.fr/hal-03782725
https://hal.inrae.fr/hal-03782725/document
https://hal.inrae.fr/hal-03782725/file/DavidescuJAA-2022.pdf
https://doi.org/10.2147/JAA.S337284

المؤلفون: Cristina Bulai Livideanu, Olivier Hermine, Carle Paul, Sophie georgin Lavialle, Sylvie Fraitag, Katia Hanssens, Clive Grattan, Gérard Guillet, Gandhi Damaj, Marie-Olivia Chandesris, Jean-Pierre Kinet, Raphaël Gaillard, Laurent Frenzel, Lawrence B. Afrin, Danielle Canioni, Stéphane Barete, Ludovic Lhermitte, Srdan Verstovsek, Christian Auclair, Ewa Jassem, Julie Agopian, Colin Mansfield, Olivier Lortholary, Patrice Dubreuil, Alain Moussy, Marek Niedoszytko

المساهمون: Centre d'infectiologie Necker-Pasteur [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut Pasteur [Paris], Centre de référence des mastocytoses (CEREMAST), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Centre hospitalier universitaire de Poitiers (CHU Poitiers), University of Gdańsk (UG), Université Pierre et Marie Curie - Paris 6 (UPMC), MD Anderson Cancer Center [Houston], The University of Texas Health Science Center at Houston (UTHealth), Norfolk & Norwich University Hospital, Norfolk & Norwich University Hospital, Colney Lane, Institut d'Hématologie de Basse-Normandie (IHBN), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER, Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Minnesota [Twin Cities] (UMN), University of Minnesota System, Histopathologie humaine et Modèles animaux, Institut Pasteur [Paris], Harvard Medical School [Boston] (HMS), Laboratoire de Biologie et de Pharmacologie Appliquée (LBPA), École normale supérieure - Cachan (ENS Cachan)-Centre National de la Recherche Scientifique (CNRS), AB Science, Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), AB Science (Paris, France)., Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Université de Toulouse (UT), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pasteur [Paris] (IP), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), MITOYAN, Louciné

المصدر: The Lancet
The Lancet, Elsevier, 2017, 389 (10069), pp.612-620. ⟨10.1016/S0140-6736(16)31403-9⟩
The Lancet, 2017, 389 (10069), pp.612-620. ⟨10.1016/S0140-6736(16)31403-9⟩

مصطلحات موضوعية: Male, 0301 basic medicine, Urticaria, MESH: Exanthema, Pyridines, [SDV]Life Sciences [q-bio], Severity of Illness Index, chemistry.chemical_compound, MESH: Aged, 80 and over, Piperidines, Clinical endpoint, MESH: Protein Kinase Inhibitors, MESH: Urticaria, MESH: Double-Blind Method, Systemic mastocytosis, MESH: Mastocytosis, Systemic, MESH: Treatment Outcome, Aged, 80 and over, MESH: Aged, education.field_of_study, MESH: Middle Aged, Masitinib, General Medicine, Middle Aged, Rash, 3. Good health, [SDV] Life Sciences [q-bio], MESH: Diarrhea, Treatment Outcome, MESH: Young Adult, Benzamides, Female, medicine.symptom, Mastocytosis, Adult, Diarrhea, medicine.medical_specialty, Population, MESH: Thiazoles, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Asthenia, Placebo, Article, Young Adult, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Double-Blind Method, Mastocytosis, Systemic, MESH: Severity of Illness Index, Internal medicine, medicine, Humans, education, Protein Kinase Inhibitors, Aged, MESH: Humans, business.industry, Hamilton Rating Scale for Depression, Repeated measures design, MESH: Adult, Exanthema, medicine.disease, MESH: Male, Surgery, Thiazoles, 030104 developmental biology, chemistry, Asthenia, business, MESH: Female

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8c5746cab0c984508b5cd7c8f0c98bb
https://doi.org/10.1016/s0140-6736(16)31403-9

المؤلفون: Laurent Gros, Stephane Betzi, Paulo De Sepulveda, Nathalie Casteran, Magali Saez-Ayala, Martine Humbert, Stéphane Audebert, Kahina Hammam, Patrice Dubreuil, Alain Moussy, Sébastien Combes, Etienne Rebuffet, Adrien Lugari, Sébastien Letard, Colin Mansfield, Sophie Lopez, Berengere Hajem, Emilie Baudelet, Xavier Morelli

المساهمون: Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), AB Science SA, AB Science, ARC Grant n° SL220130606659, MORELLI, XAVIER

المصدر: Nature Communications
Nature Communications, Nature Publishing Group, 2017, 8 (1), ⟨10.1038/s41467-017-01582-5⟩
Nature Communications, 2017, 8 (1), ⟨10.1038/s41467-017-01582-5⟩
'Nature Communications ', vol: 8, pages: 1420-1-120-11 (2017)
Nature Communications, Vol 8, Iss 1, Pp 1-11 (2017)

مصطلحات موضوعية: Models, Molecular, Proteomics, 0301 basic medicine, Polypharmacology, Pyridines, General Physics and Astronomy, [CHIM.THER]Chemical Sciences/Medicinal Chemistry, Crystallography, X-Ray, Deoxycytidine, chemistry.chemical_compound, 0302 clinical medicine, Piperidines, [CHIM.CHEM] Chemical Sciences/Cheminformatics, Phosphorylation, lcsh:Science, [SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], ComputingMilieux_MISCELLANEOUS, Multidisciplinary, [SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Structural Biology [q-bio.BM], [CHIM.ORGA]Chemical Sciences/Organic chemistry, Masitinib, [SDV.BBM.MN]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular Networks [q-bio.MN], Deoxycytidine kinase, Protein kinase inhibitor, 3. Good health, [SDV.BBM.BP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biophysics, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, 030220 oncology & carcinogenesis, Benzamides, Imatinib Mesylate, [CHIM.CHEM]Chemical Sciences/Cheminformatics, medicine.drug, [SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/Medication, [SDV.BBM.BS] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Structural Biology [q-bio.BM], medicine.drug_class, Science, [CHIM.THER] Chemical Sciences/Medicinal Chemistry, [SDV.BBM.BP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biophysics, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, Models, Biological, Article, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, Cell Line, Tumor, Deoxycytidine Kinase, medicine, [CHIM.CRIS]Chemical Sciences/Cristallography, Humans, [CHIM.CRIS] Chemical Sciences/Cristallography, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], Protein kinase A, Protein Kinase Inhibitors, Nucleoside analogue, General Chemistry, [CHIM.ORGA] Chemical Sciences/Organic chemistry, Gemcitabine, Enzyme Activation, Thiazoles, 030104 developmental biology, Imatinib mesylate, [SDV.BBM.MN] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular Networks [q-bio.MN], chemistry, A549 Cells, Drug Resistance, Neoplasm, Drug Design, Cancer research, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, lcsh:Q

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::736ab0c1b51a55de7df23e88f8a422fb
https://hal.archives-ouvertes.fr/hal-01643359/file/article55.pdf